Drawing based on the description in the official product monograph. No photo yet.
“160mg/25mg: Each brown orange, ovaloid, film-coated tablet with slightly convex faces, debossed with "HXH" on one side and "NVR" on the other contains 160 mg of valsartan and 25 mg of hydrochlorothiazide as the active ingredients”
HXH NVR pill
Pill with imprint HXH NVR is brown & orange, oval and has been identified as Valsartan and Hydrochlorothiazide 160 mg / 25 mg. It is used for high blood pressure. It is supplied by Sanis Health Inc.
Sold in Canada
Valsartan and Hydrochlorothiazide 160 mg / 25 mg
- Brand
- Valsartan HCT
- Imprint
- HXH NVR
- Strength
- Valsartan 160 mg / Hydrochlorothiazide 25 mg
- Used for
- High blood pressure
- Color
- Brown, Orange
- Shape
- Oval
- Form
- Tablet
- Manufacturer
- Sanis Health Inc
- Drug class
- ARB (blood pressure medicine)
- Sold in
- Canada
- DIN
- 02367025
Source: Health Canada's Drug Product Database and the official product monograph. Last checked .
Report a mistake
What is Valsartan and Hydrochlorothiazide used for?
Valsartan and Hydrochlorothiazide is used for high blood pressure.
- Medicine type
- ARB (blood pressure medicine); thiazide diuretic (water pill)
Official uses from the US prescribing label
Valsartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the angiotensin II receptor blocker (ARB) class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with valsartan and hydrochlorothiazide tablets.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality have also been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
Add-On Therapy
Valsartan and hydrochlorothiazide tablets may be used in patients whose blood pressure is not adequately controlled on monotherapy.
Replacement Therapy
Valsartan and hydrochlorothiazide tablets may be substituted for the titrated components.
Initial Therapy
Valsartan and hydrochlorothiazide tablets may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals.
The choice of valsartan and hydrochlorothiazide tablets as initial therapy for hypertension should be based on an assessment of potential benefits and risks.
Patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk.
Data from the high dose multifactorial trial provides estimates of the probability of reaching a target blood pressure with valsartan and hydrochlorothiazide tablets compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with valsartan and hydrochlorothiazide tablets 320 mg/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures.
Figure 1: Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8
Figure 2: Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8
Figure 3: Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8
Figure 4: Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8
For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of < 140 mmHg (systolic) and 60% likelihood of achieving < 90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on valsartan and hydrochlorothiazide tablets rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic).
From the FDA-approved label on DailyMed (published Sep 18, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your pill? Check every detail
- Your pill shows HXH NVR. The parts can be split between the two sides, so turn the pill over and check both.
- It is brown & orange, oval.
- Its score line and coating match the details on this page.
- It came from a pharmacy package that names the same drug.
Sold in Canada as Valsartan HCT by Sanis Health Inc.
In Canada: prescription only.
Ingredients
Active: Valsartan, Hydrochlorothiazide
Other pills with imprint HXH NVR
Same imprint, different listing. Check the color, size and maker against your pill.
- HXH NVR Hydrochlorothiazide and Valsartan 25 mg / 160 mg Brown & orange, oval Used for high blood pressure
- HXH NVR Hydrochlorothiazide and Valsartan 25 mg / 160 mg Brown & orange, oval Used for high blood pressure
- HXH NVR Valsartan and Hydrochlorothiazide 160 mg / 25 mg Brown, oval Used for high blood pressure
- HXH NVR Valsartan and Hydrochlorothiazide 160 mg / 25 mg Brown & orange, oval Used for high blood pressure
Pills that look similar but are different drugs
Same color and shape, different medicine. This is why the imprint matters.
-
A67
Isotretinoin 20 mg
Brown, oval, 13 mm
Used for acne and leukemia
-
25 M
Mirabegron 25 mg
Brown, oval, 12 mm
Used for overactive bladder
-
G 121
Abiraterone Acetate 500 mg
Brown, oval, 20 mm
Used for castration-resistant prostatic neoplasms
-
G38
Trandolapril and Verapamil Hydrochloride 4 mg / 240 mg
Brown, oval, 19 mm
Used for high blood pressure
-
G 320
Ranolazine 1000 mg
Brown, oval, 21 mm
Used for chest pain (angina)
-
V 7 8
Oxcarbazepine 600 mg
Brown, oval, 7 mm
Used for focal seizures
Other Valsartan and Hydrochlorothiazide pills
- LU P12 Valsartan and Hydrochlorothiazide 12.5 mg / 160 mg Brown, capsule, 16 mm Used for high blood pressure
- HHH CG Hydrochlorothiazide and Valsartan 12.5 mg / 160 mg Red, oval Used for high blood pressure
- HHH CG Hydrochlorothiazide and Valsartan 12.5 mg / 160 mg Red, oval Used for high blood pressure
- I 62 Hydrochlorothiazide and Valsartan 12.5 mg / 160 mg Red, oval Used for high blood pressure
- LU P14 Valsartan and Hydrochlorothiazide 12.5 mg / 320 mg Pink, capsule, 21 mm Used for high blood pressure
- CG HGH Hydrochlorothiazide, Valsartan 12.5 mg / 80 mg Orange, oval, 10 mm Used for high blood pressure
- LU P11 Valsartan and Hydrochlorothiazide 12.5 mg / 80 mg Pink, capsule, 13 mm Used for high blood pressure
- HGH CG Hydrochlorothiazide and Valsartan 12.5 mg / 80 mg Orange, oval Used for high blood pressure